Shares of R1 RCM Inc (NASDAQ:RCM) have earned an average rating of “Buy” from the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $13.83.
A number of equities analysts have recently weighed in on RCM shares. KeyCorp boosted their price target on R1 RCM from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Zacks Investment Research downgraded R1 RCM from a “hold” rating to a “sell” rating in a research report on Friday. BidaskClub raised shares of R1 RCM from a “hold” rating to a “buy” rating in a research report on Wednesday, July 15th. TheStreet upgraded R1 RCM from a “c” rating to a “b-” rating in a report on Wednesday. Finally, ValuEngine lowered R1 RCM from a “buy” rating to a “hold” rating in a research report on Wednesday.
Several hedge funds and other institutional investors have recently modified their holdings of RCM. Advisor Group Holdings Inc. bought a new stake in R1 RCM during the first quarter valued at about $31,000. Acadian Asset Management LLC bought a new stake in R1 RCM in the 1st quarter valued at $33,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in R1 RCM by 72.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,030 shares of the healthcare provider’s stock worth $91,000 after purchasing an additional 4,213 shares in the last quarter. Mackay Shields LLC bought a new position in shares of R1 RCM during the 1st quarter worth approximately $118,000. Finally, Aperio Group LLC bought a new stake in shares of R1 RCM in the 1st quarter worth about $119,000. 74.13% of the stock is currently owned by institutional investors and hedge funds.
RCM stock opened at $13.67 on Thursday. The company has a debt-to-equity ratio of 14.63, a current ratio of 1.18 and a quick ratio of 1.18. R1 RCM has a 12 month low of $7.12 and a 12 month high of $13.99. The company has a fifty day moving average price of $12.21 and a 200 day moving average price of $11.37. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -683.16, a price-to-earnings-growth ratio of 11.47 and a beta of 0.53.
R1 RCM (NASDAQ:RCM) last issued its earnings results on Tuesday, May 5th. The healthcare provider reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.03). The business had revenue of $320.50 million for the quarter, compared to analysts’ expectations of $318.76 million. R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company posted ($0.04) earnings per share. As a group, analysts anticipate that R1 RCM will post 0.11 earnings per share for the current year.
About R1 RCM
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
See Also: How to Trade Using Analysts Ratings
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.